Genelux Corporation (NASDAQ: GNLX) Stock Information | RedChip

Genelux Corporation (NASDAQ: GNLX) Listen to this Section


$2.03
-0.1000 ( -4.69% ) 60.6K

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Market Data


Open


$2.03

Previous close


$2.13

Volume


60.6K

Market cap


$69.39M

Day range


$2.02 - $2.16

52 week range


$1.60 - $30.44

Insider Ownership Transactions

Total Amount Purchased: 264,339.00 | $ 536,608.17

Date Type Amount Purchased Purchaser
2024-07-08 Sale -3661.00 Cappello Joseph
2024-06-07 Buy 6250.00 Smither John W
2024-06-07 Buy 6250.00 Tyree James L
2024-06-07 Buy 2500.00 Thomas John
2024-06-07 Buy 8000.00 Mirabelli Mary
2024-06-07 Buy 2500.00 Yu Yong
2024-06-07 Buy 1250.00 Smalling Ralph
2024-06-07 Buy 200000.00 Zindrick Thomas
2024-06-07 Buy 10000.00 Ryder Sean
2024-06-07 Buy 31250.00 Zak Lourie S.

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 Jul 08, 2024
4 Insider transactions 1 Jul 08, 2024
4 Insider transactions 1 Jul 08, 2024
4 Insider transactions 1 Jul 08, 2024
ars Annual reports 1 Jun 14, 2024
def Proxies and info statements 5 Jun 14, 2024
4 Insider transactions 1 Jun 07, 2024
4 Insider transactions 1 Jun 07, 2024
4 Insider transactions 1 Jun 07, 2024
4 Insider transactions 1 Jun 07, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.